drugset / Trial / NCT00710242

Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor

NCT00710242

Phase 2 Completed 263 enrolled Dilafor AB
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a Proof-of-concept study to evaluate if DF01 can prevent protracted labor. Time to delivery will be measured from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes.

Timeline

Start
2007-04
Primary completion
2009-03
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DF01 Other / unclassified 60 mg Subcutaneous

Indications